Pasithea <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Raises Executive Salaries and Grants New Stock Options
Pasithea Therapeutics Corporation has announced updated compensation arrangements for its executive officers and directors. Effective retroactively to January 1, 2025, Chief Executive Officer Dr. Tiago Reis Marques will receive a base salary increase to $533,000 with a target bonus set at 55% of his annual base salary. Chief Financial Officer Daniel Schneiderman's base salary will rise to $391,000, with a target bonus increased to 40% of his annual base salary. To conserve cash, the company amended its consulting agreement with Prof. Steinman, reducing payments from $25,000 per quarter to $1.00 per quarter. In recognition, Prof. Steinman was granted a one-time stock option award to purchase 200,000 shares at $0.715 per share, vesting fully after one year or upon a Change in Control. Additionally, Dr. Marques received options to purchase 493,341 shares, Mr. Schneiderman 317,266 shares, and certain employees a total of 352,266 shares, all at an exercise price of $0.715 per share. These options vest 33% after one year, with the remainder vesting quarterly over two years, or fully upon a Change in Control.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pasithea Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-102673), on October 27, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.